表紙:中国のオマリズマブ市場の分析 (2021年~2025年)
市場調査レポート
商品コード
1009409

中国のオマリズマブ市場の分析 (2021年~2025年)

Investigation Report on China's Omalizumab Market 2021-2025

出版日: | 発行: China Research and Intelligence | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円
中国のオマリズマブ市場の分析 (2021年~2025年)
出版日: 2021年06月04日
発行: China Research and Intelligence
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オマリズマブは、喘息治療のために現在中国で上市されている唯一のモノクローナル抗体です。 2021年前半時点では、Novartis Europharmが中国国内で唯一のメーカーとなっています。中国のオマリズマブの売上高は拡大傾向にあり、2018年~2020年のCAGRは163.2%、2020年の販売額は4161万人民元 (前年比281.5%増加) となっています。中国は喘息による死亡率が世界で最も高いことから、市場の拡大傾向は今後も継続すると考えられています。

当レポートでは、中国のオマリズマブの市場について分析し、製品の概略や許認可状況、全体的な市場規模の動向見通し、地域別の詳細動向、市場価格の動向見通し、主要企業のプロファイルと市場シェア、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

目次

第1章 オマリズマブの関連概念

  • オマリズマブの適応症
  • 中国国内のオマリズマブの開発動向
  • 中国政府のオマリズマブの承認状況
  • COVID-19が中国のオマリズマブ販売に与える影響

第2章 中国国内のオマリズマブの販売動向 (2018年~2020年)

  • オマリズマブの販売額
    • 全体的な販売額
    • 地域別の販売額
  • オマリズマブの販売量
    • 全体的な販売量
    • 地域別の販売量
  • 中国国内のオマリズマブの販売動向:剤形別 (2018年~2020年)
    • 注入剤
    • 他の剤形

第3章 中国のオマリズマブ主要メーカーの分析 (2018年~2020年)

  • 主要オマリズマブメーカーの市場シェアの分析
    • 市場シェア:販売額ベース
    • 市場シェア:販売量ベース
  • Novartis Europharm
    • 企業プロファイル
    • 中国でのオマリズマブの販売動向

第4章 中国のオマリズマブの価格動向:主要メーカー別 (2020年~2021年)

  • Novartis Europharm (XOLAIR)
  • その他の企業の分析

第5章 中国のオマリズマブ市場の将来展望 (2021年~2025年)

  • 中国のオマリズマブ市場の動向を左右する要因
    • 中国のオマリズマブ市場に対するCOVID-19の影響
    • 市場の促進要因と機会
    • 市場の脅威と課題
  • 市場規模の予測
  • 市場動向の予測
図表

List of Charts

  • Chart Patent Information About Omalizumab Injection Registration in China
  • Chart Sales Value of Omalizumab Injection over the World
  • Chart Sales Value of Omalizumab Injection in China, 2018-2020
  • Chart Sales Value of Omalizumab Injection in China by Region, 2018-2020
  • Chart Sales Volume of Omalizumab Injection in China, 2018-2020
  • Chart Sales Volume of Omalizumab Injection in China by Region, 2018-2020
  • Chart Market Share by Sales Value of Top Omalizumab Manufacturers in China, 2018-2020
  • Chart Sales Value and Volume of XOLAIR in China, 2018-2020
  • Chart Referential Prices of XOLAIR in China, 2020-2021
  • Chart Forecast on Sales Value of Omalizumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Omalizumab in China, 2021-2025
目次
Product Code: 2106508

Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europharm ' Omalizumab, which will enter the field of anti-COPD and moderate to severe persistent allergic asthma. Since then, Omalizumab has been officially launched in China. Omalizumab is the only monoclonal antibody currently on the market in China for the treatment of asthma. By the first half of 2021, Novartis Europharm is the only manufacturer in the Chinese Omalizumab market.

According to CRI's market research, Omalizumab sales have increased year by year from 2018 to 2020. At the beginning of 2020, Omalizumab was included in China's medical insurance as a treatment for respiratory diseases. During the period of the COVID-19 epidemic, the sales of Omalizumab has increased. Therefore, its sales value reached CNY41.61 million in China in 2020, with an annual growth rate of 281.5%. The CAGR of Omalizumab's sales value in the Chinese market from 2018 to 2020 is 163.2%.

CRI predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025. China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly. Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled B2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future. In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.

Topics Covered:

  • The impact of COVID-19 on China's Omalizumab market
  • Sales value of China's Omalizumab 2016-2020
  • Competitive landscape of China's Omalizumab market
  • Prices of Omalizumab in China
  • Prices of Omalizumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Omalizumab market
  • Prospect of China's Omalizumab market from 2021 to 2025

Table of Contents

1 Relevant Concept of Omalizumab

  • 1.1 Indications for Omalizumab
  • 1.2 Development of Omalizumab in China
  • 1.3 Governmental Approval of Omalizumab in China
  • 1.4 The Impact of COVID-19 on Omalizumab sales in China

2 Sales of Omalizumab in China, 2018-2020

  • 2.1 Sales Value of Omalizumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Omalizumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Omalizumab by Dosage Form in China, 2018-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Omalizumab Manufacturers in China, 2018-2020

  • 3.1 Analysis of Market Share of Major Omalizumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Novartis Europharm
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of XOLAIR (Novartis Europharm's Omalizumab) in China

4 Prices of Omalizumab for Different Manufacturers in China, 2020-2021

  • 4.1 Novartis Europharm (XOLAIR)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Omalizumab drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Omalizumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Omalizumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend